The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial
These findings indicate that fluid retention with ETA antagonism may not be caused by a direct antidiuretic effect within the kidney but is instead be an adaptive response to venodilation and increased venous capacity, which acutely tends to reduce cardiac filling pressure and cardiac output, and that fluid retention occurs in an attempt to maintain cardiac filling and cardiac output.
Authors
- K. Melissa Hallow (ORCID: https://orcid.org/0000-0002-8156-2245)
- Peter J. Greasley (ORCID: https://orcid.org/0000-0002-2529-4477)
- Hiddo J. Lambers Heerspink
- Phil Ambery (ORCID: https://orcid.org/0000-0003-2978-1886)
- Christine Ahlström (ORCID: https://orcid.org/0009-0003-0575-2295)
- David W. Boulton (ORCID: https://orcid.org/0000-0002-0668-7304)
- Bengt Hamrén (ORCID: https://orcid.org/0000-0001-5002-3399)
- Hongtao Yu (ORCID: https://orcid.org/0000-0003-2278-4478)
- Anis A. Khan (ORCID: https://orcid.org/0000-0001-8262-3022)
Institutions
- University of Georgia (US)
- University of Groningen (NL)
- The George Institute for Global Health (AU)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1111/bph.16504
- Citations
- 4
- Primary Topic
- Hemodynamic Monitoring and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- AstraZeneca